PortalPublikationenLeishmaniasis acquired by travellers to endemic regions in E...

Leishmaniasis acquired by travellers to endemic regions in Europe: a EuroTravNet multi-centre study

Standard

Leishmaniasis acquired by travellers to endemic regions in Europe: a EuroTravNet multi-centre study. / Ehehalt, Urs; Schunk, Mirjam; Jensenius, Mogens; van Genderen, Perry J J; Gkrania-Klotsas, Effrossyni; Chappuis, François; Schlagenhauf, Patricia; Castelli, Francesco; Lopez-Velez, Rogelio; Parola, Philippe; Burchard, Gerd D; Cramer, Jakob P.

in: TRAVEL MED INFECT DI, Jahrgang 12, Nr. 2, 07.01.2014, S. 167-72.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Ehehalt, U, Schunk, M, Jensenius, M, van Genderen, PJJ, Gkrania-Klotsas, E, Chappuis, F, Schlagenhauf, P, Castelli, F, Lopez-Velez, R, Parola, P, Burchard, GD & Cramer, JP 2014, 'Leishmaniasis acquired by travellers to endemic regions in Europe: a EuroTravNet multi-centre study', TRAVEL MED INFECT DI, Jg. 12, Nr. 2, S. 167-72. https://doi.org/10.1016/j.tmaid.2013.12.003

APA

Ehehalt, U., Schunk, M., Jensenius, M., van Genderen, P. J. J., Gkrania-Klotsas, E., Chappuis, F., Schlagenhauf, P., Castelli, F., Lopez-Velez, R., Parola, P., Burchard, G. D., & Cramer, J. P. (2014). Leishmaniasis acquired by travellers to endemic regions in Europe: a EuroTravNet multi-centre study. TRAVEL MED INFECT DI, 12(2), 167-72. https://doi.org/10.1016/j.tmaid.2013.12.003

Vancouver

Ehehalt U, Schunk M, Jensenius M, van Genderen PJJ, Gkrania-Klotsas E, Chappuis F et al. Leishmaniasis acquired by travellers to endemic regions in Europe: a EuroTravNet multi-centre study. TRAVEL MED INFECT DI. 2014 Jan 7;12(2):167-72. https://doi.org/10.1016/j.tmaid.2013.12.003

Bibtex

@article{be772f8844d94b05badef30e7cd0b2b3,
title = "Leishmaniasis acquired by travellers to endemic regions in Europe: a EuroTravNet multi-centre study",
abstract = "BACKGROUND: Leishmaniasis is a disease caused by protozoan parasites of the genus Leishmania. Clinical manifestations of leishmaniasis include cutaneous leishmaniasis (CL) and visceral leishmaniasis (VL). About 90% of cases occur in the tropics or subtropics but the disease is also endemic in the Mediterranean area. No systematic analysis on leishmaniasis in travellers visiting endemic areas in Europe is available.METHODS: Within the European travel medicine network EuroTravNet, we performed a retrospective analysis in travellers who acquired leishmaniasis within Europe diagnosed between 2000 and 2012.RESULTS: Forty cases of leishmaniasis (30 CL and 10 VL) were identified; the majority were acquired in Spain (n = 20, 50%), Malta and Italy (each n = 7, 18%). Median age was 48 years (range 1-79). Three of eight (37.5%) of the VL patients were on immunosuppressive therapy. The most frequent reason for travel was tourism (83%). Median duration of travel for patients with CL and VL was 2 weeks with ranges of 1-21 weeks in CL and 1-67 weeks in VL, respectively (P = 0.03).CONCLUSIONS: Health professionals should include leishmaniasis in the differential diagnosis in patients returning from southern Europe - including short-term travellers - with typical skin lesions or systemic alterations like fever, hepatosplenomegaly and pancytopenia.",
keywords = "Adolescent, Adult, Aged, Child, Child, Preschool, Endemic Diseases, Europe, Female, Humans, Infant, Leishmaniasis, Cutaneous, Leishmaniasis, Visceral, Male, Middle Aged, Retrospective Studies, Travel, Travel Medicine, Young Adult",
author = "Urs Ehehalt and Mirjam Schunk and Mogens Jensenius and {van Genderen}, {Perry J J} and Effrossyni Gkrania-Klotsas and Fran{\c c}ois Chappuis and Patricia Schlagenhauf and Francesco Castelli and Rogelio Lopez-Velez and Philippe Parola and Burchard, {Gerd D} and Cramer, {Jakob P}",
note = "Copyright {\textcopyright} 2013 Elsevier Ltd. All rights reserved.",
year = "2014",
month = jan,
day = "7",
doi = "10.1016/j.tmaid.2013.12.003",
language = "English",
volume = "12",
pages = "167--72",
journal = "TRAVEL MED INFECT DI",
issn = "1477-8939",
publisher = "Elsevier USA",
number = "2",

}

RIS

TY - JOUR

T1 - Leishmaniasis acquired by travellers to endemic regions in Europe: a EuroTravNet multi-centre study

AU - Ehehalt, Urs

AU - Schunk, Mirjam

AU - Jensenius, Mogens

AU - van Genderen, Perry J J

AU - Gkrania-Klotsas, Effrossyni

AU - Chappuis, François

AU - Schlagenhauf, Patricia

AU - Castelli, Francesco

AU - Lopez-Velez, Rogelio

AU - Parola, Philippe

AU - Burchard, Gerd D

AU - Cramer, Jakob P

N1 - Copyright © 2013 Elsevier Ltd. All rights reserved.

PY - 2014/1/7

Y1 - 2014/1/7

N2 - BACKGROUND: Leishmaniasis is a disease caused by protozoan parasites of the genus Leishmania. Clinical manifestations of leishmaniasis include cutaneous leishmaniasis (CL) and visceral leishmaniasis (VL). About 90% of cases occur in the tropics or subtropics but the disease is also endemic in the Mediterranean area. No systematic analysis on leishmaniasis in travellers visiting endemic areas in Europe is available.METHODS: Within the European travel medicine network EuroTravNet, we performed a retrospective analysis in travellers who acquired leishmaniasis within Europe diagnosed between 2000 and 2012.RESULTS: Forty cases of leishmaniasis (30 CL and 10 VL) were identified; the majority were acquired in Spain (n = 20, 50%), Malta and Italy (each n = 7, 18%). Median age was 48 years (range 1-79). Three of eight (37.5%) of the VL patients were on immunosuppressive therapy. The most frequent reason for travel was tourism (83%). Median duration of travel for patients with CL and VL was 2 weeks with ranges of 1-21 weeks in CL and 1-67 weeks in VL, respectively (P = 0.03).CONCLUSIONS: Health professionals should include leishmaniasis in the differential diagnosis in patients returning from southern Europe - including short-term travellers - with typical skin lesions or systemic alterations like fever, hepatosplenomegaly and pancytopenia.

AB - BACKGROUND: Leishmaniasis is a disease caused by protozoan parasites of the genus Leishmania. Clinical manifestations of leishmaniasis include cutaneous leishmaniasis (CL) and visceral leishmaniasis (VL). About 90% of cases occur in the tropics or subtropics but the disease is also endemic in the Mediterranean area. No systematic analysis on leishmaniasis in travellers visiting endemic areas in Europe is available.METHODS: Within the European travel medicine network EuroTravNet, we performed a retrospective analysis in travellers who acquired leishmaniasis within Europe diagnosed between 2000 and 2012.RESULTS: Forty cases of leishmaniasis (30 CL and 10 VL) were identified; the majority were acquired in Spain (n = 20, 50%), Malta and Italy (each n = 7, 18%). Median age was 48 years (range 1-79). Three of eight (37.5%) of the VL patients were on immunosuppressive therapy. The most frequent reason for travel was tourism (83%). Median duration of travel for patients with CL and VL was 2 weeks with ranges of 1-21 weeks in CL and 1-67 weeks in VL, respectively (P = 0.03).CONCLUSIONS: Health professionals should include leishmaniasis in the differential diagnosis in patients returning from southern Europe - including short-term travellers - with typical skin lesions or systemic alterations like fever, hepatosplenomegaly and pancytopenia.

KW - Adolescent

KW - Adult

KW - Aged

KW - Child

KW - Child, Preschool

KW - Endemic Diseases

KW - Europe

KW - Female

KW - Humans

KW - Infant

KW - Leishmaniasis, Cutaneous

KW - Leishmaniasis, Visceral

KW - Male

KW - Middle Aged

KW - Retrospective Studies

KW - Travel

KW - Travel Medicine

KW - Young Adult

U2 - 10.1016/j.tmaid.2013.12.003

DO - 10.1016/j.tmaid.2013.12.003

M3 - SCORING: Journal article

C2 - 24388687

VL - 12

SP - 167

EP - 172

JO - TRAVEL MED INFECT DI

JF - TRAVEL MED INFECT DI

SN - 1477-8939

IS - 2

ER -